Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept and Pembrolizumab with Radiation in HPV Oropharynx Cancer
NCT05787639Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Feb 2024
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of evorpacept in oropharyngeal cancer, sponsored by University of California, San Diego. Started Feb 2024; status: active, not recruiting.
02
Drugs
evorpacept
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT05787639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787639.